Can medications affect your fertility? Things to know

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Medical device cybersecurity has become too important to treat...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...
- Advertisement -

If you’re thinking about having a baby, your body is a vital vessel that you should take care of. Women who are planning a baby may already be aware that, among other factors, sexually transmitted illnesses, fibroids, excessive weight, and thyroid disorders can all have an influence on conception. However, it is less known that certain over-the-counter and prescription drugs might interfere with fertility. If you suspect you’re pregnant, it’s tempting to take a pregnancy test right away. But when is it safe to take a pregnancy test? Using a pregnancy test calculator, you may learn what early pregnancy tests look for and when you can take one.

We know little about the long-term impact of medications on fertility or ovarian reserve in women (egg supply). Chlorpromazine, prochlorperazine, haloperidol, risperidone, metoclopramide, methyldopa, cimetidine, some older antidepressants like amitriptyline, SSRI antidepressants like sertraline or fluoxetine, and many more can all alter ovulation and lower fertility. Immunosuppressive medications, such as cyclophosphamide, can diminish ovarian reserve. Newer immunosuppressants like tacrolimus and sirolimus, as well as antirheumatic medicines like hydroxychloroquine or methotrexate, may influence the ovaries but have not been thoroughly investigated in the long term.

Some drugs are required to address specific disorders, leaving women to deal with both the potential inability to conceive and the painful sentiments that might accompany it, such as despair, solitude, frustration, and rage. “Women with infertility issues have equivalent levels of anxiety and depression to those with cancer, HIV, or heart disease,” notes Alice Domar, Ph.D., executive director of the Domar Centers for Mind/Body Health and director of integrative care at Boston IVF and coauthor of the book Finding Calm for the Expectant Mom.

How do medications influence fertility? According to Jason Griffith, M.D., an ob-gyn and specialist in reproductive endocrinology at the Houston Fertility Institute, there are three major ways drugs can interfere with fertility, and two of them are exclusive to women. According to him, medications can affect ovulation and endometrial or uterine receptivity to pregnancy. (The third method drugs can affect sperm production is through the changes they can produce.) “A medication may affect a woman’s ability to ovulate (release an egg) or a man’s sperm count by affecting the pituitary gland’s production of follicle stimulating hormone (FSH) or luteinizing hormone (LH),” says Valerie Baker, M.D., chief of the division of reproductive endocrinology and infertility at Stanford University School of Medicine.

Clear answers about fertility and medications aren’t always obvious. “There are dozens of drugs available, and the effect on fertility for many, if not most, of them has not been adequately explored,” says Dr. Baker. “There are also several unproven over-the-counter medicines that claim to boost fertility, but there is a lack of compelling scientific proof,” Dr. Griffith says. Fortunately, most OTCs do not interfere with fertility, but it’s always a good idea to see your doctor beforehand, and avoid the following categories: NSAIDs According to Dr. Copperman, some data show that NSAIDs such as Motrin or Advil may have a minimal influence. “These can disrupt ovulation, particularly the capacity of the egg to be released by the ovary,” Dr. Griffith.

When a medicine is withdrawn, the body takes some time to recover, however the exact length varies for each substance. “Most drugs pass through the body in a matter of days, but some might interfere with regular egg production for months,” explains Dr. Copperman. Women using methotrexate, for example, should wait three months before trying to conceive. It may sometimes take a month or two for your body to return to its ideal fertility after discontinuing certain kinds of birth control. “This is most likely because the uterine lining is recovering after a long time of suppression,” adds Richard Paulson, M.D., president-elect of the American Society for Reproductive Medicine and an ob-gyn professor at the Keck School of Medicine of University of Southern California. Depo-provera (a contraceptive injection), for example, can take a particularly long time to clear the system, lingering in the body for up to 10 months after the last shot.

Alternative remedies Prescriptions are frequently unavoidable in some circumstances, such as asthma. However, for some cases, alternate techniques that are equally beneficial during the conception stage may exist. “I strongly advise women who are on an SSRI to weigh the benefits and drawbacks of continuing to take it and to consider alternative choices, such as cognitive behavior therapy, which may be just as helpful in most circumstances but has no side effects,” Dr. Domar adds. Another example of alternative therapy is acupuncture, a supplemental medicine used to relieve pain. When attempting to conceive or while pregnant, most doctors would prefer that women take as little drugs as possible. “It’s a good idea to sit down with your doctor before getting pregnant to examine the safety of each one and to try to either switch to safer ones or try non-pharmaceutical ways,” Dr. Domar advises. If a regimen is required (for example, chemotherapy for cancer), explore the idea of freezing eggs before commencing the treatment.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Medical device cybersecurity has become too important to treat...

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »